HIV/STD Laboratory Core

DESCRIPTIONPERSONNELRIGORSERVICESPUBLICATIONS

HIV/STD Laboratory CORE DESCRIPTION

The HIV/STD Laboratory Core of the UNC CFAR offers services and collaborations to HIV researchers for their basic and clinical research projects. The Core provides a GCLP environment for specimen processing and testing.

The HIV/STD Laboratory Core consults and collaborates with researchers at UNC-CH, RTI International, and FHI 360 (as well as outside researchers). Our contributions to recent research projects include:

developing flow cytometry assays and cytokine ELISA and multiplex bead array panels
providing instrumentation, e.g. ELISPOT reader
sequencing of HIV from patients
testing new microbiologic diagnostic assays on a variety of specimen types
testing compounds for anti-HIV activity
measuring prostate specific antigen (PSA) as a marker of sexual activity
training of personnel in virus work and various assays

The Core serves as a repository for long- and short-term storage of biological specimens from HIV+ patients in the UNC CFAR HIV Clinical Cohort (UCHCC) and maintains a current CDC-USPHS permit for importing HIV+ specimens from foreign countries.

Researchers and clinicians can request services using the button at the top of the page and you can contact us by our email address.

HIV/STD Laboratory CORE NEWS

The HIV/STD Laboratory Core is located on the 5th floor of Taylor Hall, which is adjacent to MBRB. The Basic Science part of the Core lab is in 22-059 Lineberger Cancer Center.

Kristina De Paris, Ph.D.

Core Director

Dr. De Paris is a Professor in the Department of Microbiology and Immunology. The research in the De Paris lab is centered around HIV. The lab is pursuing HIV prevention studies with the goal to understand the determinants that drive the development of broadly neutralizing antibodies against HIV by vaccination. A second area of HIV research is focused on HIV in pregnancy to define biological mechanisms that are associated with higher risk of adverse birth outcomes in women with HIV.

Closely linked to this area of research is an interest in the link between infant immune development and increased susceptibility to infectious diseases in healthy infants and/or infants born to mothers with HIV.

The University of North Carolina at Chapel Hill
Chapel Hill, NC
abelk@med.unc.edu
Office phone: 919-843-9560

Robert Krysiak, MSc

Associate Core Director

Robert Krysiak, MSc Robert Krysiak is a Research Associate at the Institute of Global Health and Infectious Diseases. Rob earned his Master of Science in Microbiology from Thomas Jefferson University and has worked at UNC since 1997. He is a clinical microbiologist and a recognized expert in building and maintaining laboratory systems in resource-limited settings. He has developed an extensive background in international laboratory development and management in nearly fifteen countries in support of public health research targeting infectious diseases, particularly in Sub-Saharan Africa. He was most recently the Laboratory Director at UNC Project-Malawi before joining the HSL Core.

The University of North Carolina at Chapel Hill
Chapel Hill, NC
robert_krysiak@med.unc.edu

John Schmitz, Ph.D.

Clinical Consultant

Dr. Schmitz is a Professor of Pathology and Laboratory Medicine and Microbiology/Immunology and directs the Histocompatibility, Flow Cytometry and Clincal Immunology Laboratories at UNC Hospitals. Dr. Schmitz has experiences in the use of cytokine assays, flow cytometry including cell surface and intracellular cytokine assays as well as lymphocyte proliferation assays. He has used that experience in validating and implementing assays for HIV related research for over 15 years. Prior to establishing the Immunology Core Dr. Schmitz served for 8 years as the Director of the UNC Immunology Support Laboratory, one of 8 Immunology Cores within the ACTG. In addition to his experience providing support of basic, translational and clinical studies of HIV infection, Dr. Schmitz has extensive experience in diagnostic Immunology as director of the Clinical Immunology, Flow Cytometry and Histocompatibility Laboratories at UNC Hospitals. Dr. Schmitz’ 25 years of clinical research experience include assessment of antigen-specific humoral and cell-mediated immune responses, quantitation of soluble markers, immunogenetic testing and molecular diagnostics of infectious diseases.

The University of North Carolina at Chapel Hill
CB# 7600
Chapel Hill, NC
jschmitz@unch.unc.edu
Fax: 919-966-0486
Office Phone: 919-966-8453

Kiera William

Kiera Williams

Research Technician

Laura Langer

Research Technician

Ryan Research Specialist

Ryan Hansen

Research Specialist

Aidyn Cada

Research Technician

UPDATED November 2019

RIGOR AND REPRODUCIBILITY FOR CFAR HIV/STD LABORATORY CORE

Eight steps to Rigorous and Reproducible Experiments in Biomolecular Research at UNC:

If using a core facility, consult with the core staff in the planning stage. Consult with a statistician if you need help developing a Power Analysis to assure that your results will be adequately powered.
Design your experiment with sufficient controls (rigor) and replicates (reproducibility).
Assure that ALL of your reagents (antibodies, cell lines, mice) are fully validated (see below).
Have a clear and detailed protocol (SOP) and data analysis plan. Assure that the protocol is strictly followed or that any deviation is well documented.
Assure that the staff or students performing the experiment are well trained and understand each step and the importance of performing them precisely.
Use only well-maintained instrumentation, preferably maintained and operated in a core facility with expert staff (see #1 above).
Document all steps, reagents, equipment and data analysis methods used in the experiment. Assure that the both the documentation and the data itself are properly stored in a safe data management repository.
Acknowledge the Cancer Center Support Grant (P30 CA016086) (if applicable), other grants that support the core, the core (by name), and core staff in publications.

Guide to Rigor and Reproducibility for the CFAR HIV/STD Laboratory Core

Consult with the core staff in the planning stage. – Contact Julie Nelson, Core Director at jnelson@med.unc.edu or 919-966-6872
Depending on the type of testing needed, appropriate controls and standards will be included. Replicates are important and can vary depending on the type of testing and power calculations. Flow cytometry, soluble marker quantitation, HIV quantitation, PSA detection, and HIV inhibition assays all have different controls and standards. Talk to us about the appropriate controls, standards, and replicates for your project.
Validation of methods must be done when using a kit for a different sample type than the kit was designed for (soluble markers, etc.). The Core has validated methods for HIV quantitation from dried blood spots and PSA detection from vaginal swabs, for instance.
The HIV/STD Laboratory Core provides training to ensure that all investigators are properly training in our technology unless we are contracted to do the work within the core. Training is provided includes BSL2+ work with HIV or human blood, MagPix and ELISA quantitation, ELISPOT reader use, flow on HIV-infected cells, and in vitro work with HIV. Contact us for more information.
The CFAR HIV/STD Laboratory Core participates in external quality assurance for PBMC processing through the IQA and is CAP/CLIA accredited. The Core is also GCLP compliant in accordance with NIH DAIDS Network oversight.
All equipment in the HIV/STD Laboratory Core is maintained per GCLP, CAP, or manufacturer’s instructions. In addition, QC measures are in place per GCLP and CAP.
Detailed descriptions of experimental procedures and validations, including sample storage and processing, are documented electronically and in notebooks within the Core.
Please acknowledge the UNC Center for AIDS Research HIV/STD Laboratory Core in your publications. Instructions for acknowledgment can be found here: https://unccfar.org/acknowledge-the-cfar/

UPDATED JUNE 2023

Services	UNC ($)	Non-UNC ($)
Abbott VL	172	268
T cell T mag	141	220
ELISPOT outside CFAR	60	94
MagPix/LX200	86	134
Serum with additives	64	100
PBMC to 50ml blood CRS	160	249
1 spin CRS	55	85
2 spin CRS	55	86
Aliquots CRS	55	85
DBS (supplies only)	5	8
Leukopak (handling only)	225	361

HLA test from Histogenetics	195	303
HLA DNA extraction	20	31
Phlebotomy	60	94
Donor recruitment	20	31
Specimen handling	35	54
Dry ice shipping	118	183
LN2 shipping	180	279
Storage in -20 or -80 freezer; per box per month	1	2
Storage in liquid nitrogen freezer; per box per month	2	4
Assay labor	60	93
Analysis	100	156
Consultation	110	172

*Cost will be determined for each project to include kits, supplies, and labor
All projects with non-UNC funds will have an additional 55.5% fee

PUBLICATIONS

2021

Abdo M, Wu X, Sharma A, Tassiopoulos KK, Brown TT, Koletar SL, Yin MT and Erlandson KM. Regional Differences in Risk of Recurrent Falls Among Older U.S. Women and Men with HIV in the HIV Infection, Aging, and Immune Function Long-Term Observational Study. AIDS Res Hum Retroviruses. 2022.

Bosch RJ, Gandhi RT, Mar H, Eron JJ, Cyktor JC, McMahon DK, Mellors JW and ACTG A5341s Team. Associations between multiple measures of HIV-1 persistence on suppressive antiretroviral therapy. J Infect Dis. 2022.

Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK and ACTIV-2/A5401 Team. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv. 2021. PMC8750705.

Brown LK, Chernoff M, Kennard BD, Emslie GJ, Lypen K, Buisson S, Weinberg A, Whiteley LB, Traite S, Krotje C, Harriff L, Townley E, Bunch A, Purswani M, Shaw R, Spector SA, Agwu A, Shapiro DE and IMPAACT 2002 team. Site-Randomized Controlled Trial of a Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States. J Acquir Immune Defic Syndr. 88(5):497-505. 2021. PMC8585710.

Budhwani H, Gakumo CA, Yigit I, Rice WS, Fletcher FE, Whitfield S, Ross S, Konkle-Parker DJ, Cohen MH, Wingood GM, Metsch LR, Adimora AA, Taylor TN, Wilson TE, Weiser SD, Sosanya O, Goparaju L, Gange S, Kempf MC, Turan B and Turan JM. Patient Health Literacy and Communication with Providers Among Women Living with HIV: A Mixed Methods Study. AIDS Behav. 2021.

Budhwani H, Yigit I, Ofotokun I, Konkle-Parker DJ, Cohen MH, Wingood GM, Metsch LR, Adimora AA, Taylor TN, Wilson TE, Weiser SD, Kempf MC, Sosanya O, Gange S, Kassaye S, Turan B and Turan JM. Examining the Relationships Between Experienced and Anticipated Stigma in Health Care Settings, Patient-Provider Race Concordance, and Trust in Providers Among Women Living with HIV. AIDS Patient Care STDS. 35(11):441-448. 2021. PMC8817693.

Caro-Vegas C, Ramirez C, Landis J, Adimora AA, Strickler H, French AL, Ofotokun I, Fischl M, Seaberg EC, Wang CJ, Spence AB and Dittmer DP. Molecular profiling of breast and lung cancer in women with HIV reveals high tumor mutational burden. AIDS. 2021.

Cedarbaum ER, Ma Y, Adimora AA, Bamman M, Cohen MH, Fischl MA, Gustafson D, Matsushita K, Ofotokun I, Plankey M, Seaberg EC, Sharma A and Tien PC. Peripheral artery disease and physical function in women with and without HIV. AIDS. 36(3):347-354. 2022. PMC8795474.

Chen J, Titanji K, Sheth AN, Gandhi R, McMahon D, Ofotokun I, Weitzmann MN, De Paris K and Dumond JB. The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study. Immun Ageing. 19(1):4. 2022. PMC8722153.

Chen JS, Matoga M, Massa C, Tegha G, Ndalama B, Bonongwe N, Mathiya E, Jere E, Banda G, Loftis AJ,Lancaster KE, Miller WC, Hoffman IF and Cohen MS. Effects of Urethritis on Human Immunodeficiency Virus (HIV) in Semen: Implications for HIV Prevention and Cure. Clin Infect Dis. 73(7):e2000-e2004. 2021. PMC8492110.

Chen JS, Pettifor AE, Nelson JAE, Phiri S, Pasquale DK, Kumwenda W, Kamanga G, Cottrell ML, Sykes C, Kashuba ADM, Tegha G, Krysiak R, Thengolose I, Cohen MS, Hoffman IF, Miller WC and Rutstein SE. Blood and genital fluid viral load trajectories among treated and untreated persons with acute HIV infection in Malawi. J Acquir Immune Defic Syndr. 2022.

Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes M, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ and ACTIV-2/A5401 Team. Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy. medRxiv. 2021. PMC8452115.

Conroy AA, Jain JP, Sheira L, Frongillo EA, Neilands TB, Cohen MH, Wilson TE, Chandran A, Adimora AA, Kassaye S, Sheth AN, Fischl MA, Adedimeji A, Turan JM, Tien PC and Weiser SD. Mental Health Mediates the Association Between Gender-Based Violence and HIV Treatment Engagement in US Women. J Acquir Immune Defic Syndr. 89(2):151-158. 2022. PMC8752473.

Crowell TA, Ritz J, Coombs RW, Zheng L, Eron JJ, Mellors JW, Dragavon J, van Zyl GU, Lama JR, Ruxrungtham K, Grinsztejn B, Arduino RC, Fox L, Ananworanich J, Daar ES and ACTG A5354/EARLIER Study Team. Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation. Clin Infect Dis. 73(3):e643-e651. 2021. PMC8326583.

D’Souza G, Tong W, Gustafson D, Alcaide ML, Lahiri CD, Sharma A, French AL, Palella FJ, Kempf MC, Mimiaga MJ, Ramirez C, Kassaye S, Rinaldo CR, Brown TT, Tien PC and Adimora AA. SARS-CoV-2 Infection Among People Living With HIV Compared With People Without HIV: Survey Results From the MACS-WIHS Combined Cohort Study. J Acquir Immune Defic Syndr. 89(1):1-8. 2022. PMC8667184.

Daubert E, French AL, Burgess HJ, Sharma A, Gustafson D, Cribbs SK, Weiss DJ, Ramirez C, Konkle-Parker D, Kassaye S and Weber KM. Association of Poor Sleep With Depressive and Anxiety Symptoms by HIV Disease Status: Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 89(2):222-230. 2022. PMC8740603.

Deese J, Wang M, Lapple D, Nelson JAE, Kuerten B, Steiner MJ, Chen PL and Hobbs MM. What’s Sex Got to Do With It? Understanding Potential Confounding and Exposure Misclassification in Mechanistic Sexually Transmitted Infection Research. J Infect Dis. 224(1):137-140. 2021. PMC8427711.

Diepstra KL, Barr L, Palm D, Hogg E, Mollan KR, Henley L, Stover AM, Simoni JM, Sugarman J, Brown B, Sauceda JA, Deeks S, Fox L, Gandhi RT, Smith D, Li JZ and Dube K. Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study. AIDS Res Hum Retroviruses. 37(6):489-501. 2021. PMC8213012.

Dunkle LM, Kotloff KL, Gay CL, Anez G, Adelglass JM, Barrat Hernandez AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruiz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F and 2019nCoV-301 Study Group. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 386(6):531-543. 2022. PMC8693692.

Fischer WA, 2nd, Eron JJ, Jr., Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F and Painter WP. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 14(628):eabl7430. 2022.

Friedland A, Hernandez AF, Anstrom KJ, Chen-Lim ML, Cohen LW, Currier JS, Forrest CB, Fraser R, Fraulo E, George A, Handberg E, Jackman J, Koellhoffer J, Lawrence D, Leverty R, McAdams P, McCourt B, Mickley B, Naqvi SH, O’Brien EC, Olson R, Prater C, Rothman RL, Shenkman E, Shostak J, Turner KB, Webb L, Woods C, Naggie S and HERO Research Program. Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform. Contemp Clin Trials. 109:106525. 2021. PMC8349387.

Friedman MR, Kempf MC, Benning L, Adimora AA, Aouizerat B, Cohen MH, Hatfield Q, Merenstein D, Mimiaga MJ, Plankey MW, Sharma A, Sheth AN, Ramirez C, Stosor V, Wagner MCE, Wilson TE, D’Souza G and Weiss DJ. Prevalence of COVID-19-Related Social Disruptions and Effects on Psychosocial Health in a Mixed-Serostatus Cohort of Men and Women. J Acquir Immune Defic Syndr. 88(5):426-438. 2021. PMC8575096.

Gay CL, Bosch RJ, McKhann A, Moseley KF, Wimbish CL, Hendrickx SM, Messer M, Furlong M, Campbell DM, Jennings C, Benson C, Overton ET, Macatangay BJC, Kuritzkes DR, Miller E, Tressler R, Eron JJ, Hardy WD and A5370 Team. Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV. J Acquir Immune Defic Syndr. 87(5):e234-e236. 2021. PMC8263135.

Gay CL, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Moeser MJ, Allard B, Kirchherr JL, Clohosey M, Raines SLM, Montefiori DC, Shen X, Gorelick RJ, Gama L, McDermott AB, Koup RA, Mascola JR, Floris-Moore M, Kuruc JD, Ferrari G, Eron JJ, Archin NM and Margolis DM. Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. J Infect Dis. 225(5):856-861. 2022. PMC8889279.

Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O’Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Immune Assays Team, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, and United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 375(6576):43-50. 2022.

Hurt CB, Morrison AS, Guy J, Mobley VL, Dennis AM, Barrington C, Samoff E, Hightow-Weidman LB, McNeil CJ, Carry MG, Hogben M and Sena AC. Beyond Disease Intervention: Exploring an Expanded Role for Partner Services in the MATRix-NC Demonstration Project. Sex Transm Dis. 49(2):93-98. 2022.

Ismail SD, Riou C, Joseph SB, Archin NM, Margolis DM, Perelson AS, Cassidy T, Abrahams MR, Moeser M, Council OD, McKinnon LR, Osman F, Karim QA, Abdool Karim SS, Swanstrom R, Williamson C, Garrett NJ and Burgers WA. Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. Clin Infect Dis. 73(8):1528-1531. 2021. PMC8528395.

Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL, Palella FJ, Jr. and ACTG A5322 Study Team. Incorporating Frailty Into the Pooled Cohort Equations to Predict Cardiovascular Disease Among Persons With HIV. J Acquir Immune Defic Syndr. 87(3):971-977. 2021. PMC8192418.

Kimani S, Painschab MS, Kaimila B, Kasonkanji E, Zuze T, Tomoka T, Mulenga M, Nyasosela R, Chikasema M, Mtangwanika A, Chawinga M, Mhango W, Nicholas S, Chimzimu F, Kampani C, Krysiak R, Lilly A, Randall C, Seguin R, Westmoreland KD, Montgomery ND, Fedoriw Y and Gopal S. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial. Lancet Glob Health. 9(7):e1008-e1016. 2021.

Knittel AK, Rudolph JE, Shook-Sa BE, Edmonds A, Ramirez C, Cohen M, Taylor T, Adedimeji A, Michel KG, Milam J, Cohen J, Donohue JD, Foster A, Fischl MA, Long DM and Adimora AA. Self-Reported Sexually Transmitted Infections After Incarceration in Women with or at Risk for HIV in the United States, 2007-2017. J Womens Health (Larchmt). 2021.

Kreitchmann R, Stek A, Best BM, Capparelli E, Wang J, Shapiro D, Chakhtoura N, Mirochnick M, Eke AC and IMPAACT P1026s protocol team. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens. Contraception. 105:67-74. 2022. PMC8678338.

Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR, Fairlie L, Winckler JL, Slade G, Meyers T and IMPAACT P1101 Team. Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. J Pediatric Infect Dis Soc. 10(2):201-204. 2021. PMC7996637.

Kuniholm MH, Vasquez E, Appleton AA, Kingsley L, Palella FJ, Budoff M, Michos ED, Fox E, Jones D, Adimora AA, Ofotokun I, D’Souza G, Weber KM, Tien PC, Plankey M, Sharma A and Gustafson DR. Cardiovascular risk score associations with frailty in men and women with or at risk for HIV. AIDS. 36(2):237-347. 2022. PMC8711611.

Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamani J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B and HPTN 083 Study Team. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 385(7):595-608. 2021. PMC8448593.

Li JZ, Aga E, Bosch R, Pilkinton M, Kroon E, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Anaworanich J, Coombs R, Mellors J, Landay A, Macatangay B, Deeks S, Gandhi RT, Smith DM and ACTG A5345 Study Team. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2021.

Liu C, Hufnagel K, O’Connell CM, Goonetilleke N, Mokashi N, Waterboer T, Tollison TS, Peng X, Wiesenfeld HC, Hillier SL, Zheng X and Darville T. Reduced Endometrial Ascension and Enhanced Reinfection Associated with IgG Antibodies to Specific Chlamydia trachomatis Proteins in Women at Risk for Chlamydia. J Infect Dis. 2021.

MacBrayne CE, Rutstein RM, Wiznia AA, Graham B, Alvero CG, Fairlie L, Lypen K, George KH, Townley E, Moye J, Jr., Costello DG, Reding CA, Barroso Hofer C, Crauwels HM, Woot de Trixhe X, Tambuyzer L, Vanveggel S, Opsomer M, Kiser JJ and the IMPAACT P1090 Protocol Team. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS. 35(9):1413-1421. 2021. PMC8270511.

Maia CMA, Pasetto S, Raimundo ESJP, Tavares JF, Costa E and Murata RM. Anandenanthera colubrina (Vell.) Brenan as an inhibitor of HIV-1 BaL infection. Nat Prod Res.1-5. 2021.

Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, McCauley M, Cummings V, Ahmed S, Haines CD, Bushman LR, Petropoulos C, Persaud D, Adeyeye A, Kofron R, Rinehart A, St Clair M, Rooney JF, Pryluka D, Coelho L, Gaur A, Middelkoop K, Phanuphak N, Cohen MS, Hendrix CW, Anderson P, Hanscom B, Donnell D, Landovitz RJ and Eshleman SH. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. J Infect Dis. 224(9):1581-1592. 2021. PMC8599849.

Masters MC, Perez J, Wu K, Ellis RJ, Goodkin K, Koletar SL, Andrade A, Yang J, Brown TT, Palella FJ, Sacktor N, Tassiopoulos K and Erlandson KM. Baseline Neurocognitive Impairment (NCI) Is Associated With Incident Frailty but Baseline Frailty Does Not Predict Incident NCI in Older Persons With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 73(4):680-688. 2021. PMC8499706.

Meanley S, Choi SK, Thompson AB, Meyers JL, D’Souza G, Adimora AA, Mimiaga MJ, Kempf MC, Konkle-Parker D, Cohen MH, Teplin LA, Murchison L, Rubin LH, Rubtsova AA, Weiss DJ, Aouizerat B, Friedman MR, Plankey MW and Wilson TE. Short-term binge drinking, marijuana, and recreational drug use trajectories in a prospective cohort of people living with HIV at the start of COVID-19 mitigation efforts in the United States. Drug Alcohol Depend. 231:109233. 2022. PMC8709730.

Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, Goecker EA, Premkumar L, Wolfe CR, Szewczyk LJ, Alabanza PL, Loftis AJ, Degli-Angeli EJ, Brown AJ, Dragavon JA, Won JJ, Keys J, Hudgens MG, Fang L, Wohl DA, Cohen MS, Baric RS, Coombs RW, Sheahan TP and Fischer WA. Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. Clin Infect Dis. 2021.

Momper JD, Wang J, Stek A, Shapiro DE, Powis KM, Paul ME, Badell ML, Browning R, Chakhtoura N, Denson K, Rungruengthanakit K, George K, Capparelli EV, Mirochnick M, Best BM and IMPAACT P1026s Protocol Team. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV. J Acquir Immune Defic Syndr. 89(3):303-309. 2022. PMC8837686.

Mulligan N, Salama E, Momper JD, Capparelli EV, Stek A, Chakhtoura N, Mirochnick M, Best BM and IMPAACT P1026s Protocol Team. Lopinavir and tenofovir interaction observed in non-pregnant adults altered during pregnancy. J Clin Pharm Ther. 46(5):1459-1464. 2021. PMC8448937.

Nguyen NC, Luong TN, Le VT, Hobbs M, Andridge R, Casterline J and Gallo MF. Effectiveness of erectogenic condom against semen exposure among women in Vietnam: Randomized controlled trial. PLoS One. 17(2):e0263503. 2022. PMC8853499.

Painschab MS, Kohler R, Kimani S, Mhango W, Kaimila B, Zuze T, Mithi V, Kasonkanji E, Mumba N, Nyasosela R, Wheeler S and Gopal S. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis. Lancet Glob Health. 9(9):e1305-e1313. 2021. PMC8403678.

Philbin MM, Parish C, Kinnard EN, Reed SE, Kerrigan D, Alcaide ML, Cohen MH, Sosanya O, Sheth AN, Adimora AA, Cocohoba J, Goparaju L, Golub ET, Fischl M and Metsch LR. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women’s Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States. AIDS Behav. 25(3):667-678. 2021. PMC7886938.

Piscitelli J, Nikanjam M, Best BM, Acosta E, Mirochnick M, Clarke DF, Capparelli EV and Momper JD. Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation. J Acquir Immune Defic Syndr. 89(1):108-114. 2022. PMC8665018.

Presti RM, Yeh E, Williams B, Landay A, Jacobson JM, Wilson C, Fichtenbaum CJ, Utay NS, Dube MP, Klingman KL, Estes JD, Flynn JK, Loftin A, Brenchley JM, Andrade A, Kitch DW and Overton ET. A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy. Open Forum Infect Dis. 8(12):ofab550. 2021. PMC8651169.

Rittenhouse KJ, Mwape H, Nelson JAE, Mwale J, Chipili G, Price JT, Hudgens M, Stringer EM, De Paris K, Vwalika B and Stringer JSA. Maternal HIV, antiretroviral timing, and spontaneous preterm birth in an urban Zambian cohort: the role of local and systemic inflammation. AIDS. 35(4):555-565. 2021. PMC7944942.

Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, Morse GD, Squires KE, Howell BJ, Wu G, Hosey L, Sieg S, Ehui L, Giguel F, Coxen K, Dobrowlski C, Gandhi M, Deeks S, Chomont N, Connick E, Godfrey C, Karn J, Kuritzkes DR, Bosch RJ, Gandhi RT and A5366 study team. Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial). Clin Infect Dis. 2022.

Sellers SA, Edmonds A, Ramirez C, Cribbs SK, Ofotokun I, Huang L, Morris A, McCormack MC, Kunisaki KM, D’Souza G, Rivera MP, Drummond MB and Adimora AA. Optimal lung cancer screening criteria among persons living with HIV. J Acquir Immune Defic Syndr. 2022.

Sheth AN, Adimora AA, Golub ET, Kassaye SG, Rana A, Westreich D, Cyriaque JW, Parish C, Konkle-Parker D, Jones DL, Kempf MC, Ofotokun I, Kanthula RM, Donohue J, Raccamarich P, Tisdale T, Ramirez C, Warren-Jeanpiere L, Tien PC and Alcaide ML. Study of Treatment and Reproductive Outcomes Among Reproductive-Age Women With HIV Infection in the Southern United States: Protocol for a Longitudinal Cohort Study. JMIR Res Protoc. 10(12):e30398. 2021. PMC8726043.

Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D and Sulkowski M. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022.

Sugarman J, Donnell DJ, Hanscom B, McCauley M, Grinsztejn B and Landovitz RJ. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. Lancet HIV. 8(11):e723-e728. 2021.

Takuva S, Karuna ST, Juraska M, Rudnicki E, Edupuganti S, Anderson M, De La Grecca R, Gaudinski MR, Sehurutshi A, Orrell C, Naidoo L, Valencia J, Villela LM, Walsh SR, Andrew P, Karg C, Randhawa A, Hural J, Gomez Lorenzo MM, Burns DN, Ledgerwood J, Mascola JR, Cohen M, Corey L, Mngadi K, Mgodi NM, and the HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Study Teams. Infusion reactions after receiving the broadly neutralizing antibody VRC01 or placebo to reduce HIV-1 acquisition: Results from the phase 2b Antibody Mediated Prevention (AMP) randomized trials. J Acquir Immune Defic Syndr. 2021.

Tsai K, Bogerd HP, Kennedy EM, Emery A, Swanstrom R and Cullen BR. Epitranscriptomic addition of m(6)A regulates HIV-1 RNA stability and alternative splicing. Genes Dev. 35(13-14):992-1004. 2021. PMC8247604.

Vavro C, Ruel T, Wiznia A, Montanez N, Nangle K, Horton J, Buchanan AM, Stewart EL and Palumbo P. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study. Antimicrob Agents Chemother. 66(1):e0164521. 2022. PMC8765298.

Waltmann A, Duncan J, Pier G, Cywes-Bentley C, Cohen M and Hobbs M. Experimental urethral infection with Neisseria gonorrhoeae. In: Bagnoli F, Del Giudice G, Phogat S and Rappuoli R, eds. Human Challenge Studies for Vaccine Development. Vol In press. New York, NY: Springer Nature; 2022.

Webster CM, Kasaro MP, Price JT, Stringer EM, Wiesen CA, Vwalika B and Stringer JSA. Seroreduction of syphilis non-treponemal titers during pregnancy for women with and without HIV co-infection. Int J Gynaecol Obstet. 2022.

Willis SK, Aiello AE, Chatterjea D, Nelson JA, Hibberd PL and Harlow BL. Characterizing Differences in Thymic Function in Women With and Without Vulvodynia: A Community-Based Study. J Low Genit Tract Dis. 25(4):296-302. 2021.

Wyles DL, Kang M, Matining RM, Murphy RL and Peters MG. Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 8(12):ofab511. 2021. PMC8677564.

Xu Y, Weideman AM, Abad-Fernandez M, Mollan KR, Kallon S, Samir S, Warren JA, Clutton G, Roan N, Adimora AA, Archin N, Kuruc J, Gay C, Hudgens MG and Goonetilleke N. Reliable Estimation of CD8 T Cell Inhibition of In Vitro HIV-1 Replication. Front Immunol. 12:666991. 2021. PMC8278574.

Zhao S, Gockenbach M, Grimstein M, Sachs HC, Mirochnick M, Struble K, Belew Y, Wang J, Capparelli EV, Best BM, Johnson T, Momper JD and Maharaj AR. Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development. Front Pediatr. 9:721059. 2021. PMC8550258.

Zhou S, Sizemore S, Moeser M, Zimmerman S, Samoff E, Mobley V, Frost S, Cressman A, Clark M, Skelly T, Kelkar H, Veluvolu U, Jones C, Eron J, Cohen M, Nelson JAE, Swanstrom R and Dennis AM. Near Real-Time Identification of Recent Human Immunodeficiency Virus Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by Multiplexed Primer ID-Next-Generation Sequencing in North Carolina. J Infect Dis. 223(5):876-884. 2021. PMC7938176.

2020

Campbell EM, Patala A, Shankar A, Li JF, Johnson JA, Westheimer E, Gay CL, Cohen SE, Switzer WM and Peters PJ. Phylodynamic Analysis Complements Partner Services by Identifying Acute and Unreported HIV Transmission. Viruses. 12(2):145. 2020. PMC7077189.

Curtis AD, Dennis M, Eudailey J, Walter KL, Cronin K, Alam SM, Choudhary N, Tuck RH, Hudgens M, Kozlowski PA, Pollara J, Ferrari G, Van Rompay KKA, Permar S and De Paris K. HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. mSphere. 5(2):e00162-00120. 2020. PMC7096624.

Dube K, Hosey L, Starr K, Barr L, Evans D, Hoffman E, Campbell D, Simoni J, Sugarman J, Sauceda J, Brown B, Diepstra KL, Godfrey C, Kuritzkes DR, Wohl DA, Gandhi R and Scully E. Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group (ACTG) 5366. AIDS Res. Hum. Retroviruses. 36(4):268-282. 2020. PMC7185351

Dumond JB, Bay CP, Nelson JAE, Davalos A, Edmonds A, De Paris K, Sykes C, Anastos K, Sharma R, Kassaye S, Tamraz B, French AL, Gange S, Ofotokun I, Fischl MA, Vance DE and Adimora AA. Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine. Antimicrob. Agents Chemother. [Epub ahead of print]. 2020.

Fedoriw Y, Selitsky S, Montgomery ND, Kendall SM, Richards KL, Du W, Tomoka T, Mulenga M, Parker JS, Dave SS and Gopal S. Identifying transcriptional profiles and evaluating prognostic biomarkers of HIV-associated diffuse large B-cell lymphoma from Malawi. Mod. Pathol. [Epub before print]. 2020.

Gay CL, Kuruc JD, Falcinelli SD, Warren JA, Reifeis SA, Kirchherr JL, James KS, Dewey MG, Helms A, Allard B, Stuelke E, Gamble A, Plachco A, Gorelick RJ, Eron JJ, Hudgens M, Garrido C, Goonetilleke N, DeBenedette MA, Tcherepanova IY, Nicolette CA, Archin NM and Margolis DM. Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. Sci. Rep. 10(1):5134. 2020. PMC7083965.

Montgomery ND, Randall C, Painschab M, Seguin R, Kaimila B, Kasonkanji E, Zuze T, Krysiak R, Sanders MK, Elliott A, Miller MB, Kampani C, Chimzimu F, Mulenga M, Damania B, Tomoka T, Fedoriw Y, Dittmer DP and Gopal S. High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi. Cancer Med. 9(2):552-561. 2020. PMC6970037.

Muss HB, Smitherman A, Wood WA, Nyrop K, Tuchman S, Randhawa PK, Entwislte A, R., Mitin N and Shachar SS. P16 A Biomarker of Aging and Tolerance for Cancer Therapy. Transl Cancer Res.[Epub before print]. 2020.

Nelson JAE, De Paris K, Ramirez C, Edmonds A, Mollan KR, Bay CP, Compliment K, Herold BC, Anastos K, Minkoff H, Kassaye S, Seidman DL, French AL, Golub ET, Sheth AN, Ochsenbauer C, Swanstrom R, Eron JJ and Adimora AA. Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma. AIDS. 34(1):39-46. 2020. PMC6910230.

Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, Mattingly C, Ho PT, Schoof N, Cammon CG, Tharp GK, Kanke M, Wang Z, Cleary RA, Upadhyay AA, De C, Wills SR, Falcinelli SD, Galardi C, Walum H, Schramm NJ, Deutsch J, Lifson JD, Fennessey CM, Keele BF, Jean S, Maguire S, Liao B, Browne EP, Ferris RG, Brehm JH, Favre D, Vanderford TH, Bosinger SE, Jones CD, Routy JP, Archin NM, Margolis DM, Wahl A, Dunham RM, Silvestri G, Chahroudi A and Garcia JV. Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling in vivo. Nature. 578(7793):160-165. 2020. PMC7111210.

Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Opsomer M and AMBER study group. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 34(5):707-718. 2020. PMCID Number: Journal In Process.

Rohner E, Rahangdale L, Sanusi B, Knittel AK, Vaughan L, Chesko K, Faherty B, Tulenko SE, Schmitt JW, Romocki LS, Sivaraman V, Nelson JAE and Smith JS. Test Accuracy of Human Papillomavirus in Urine for Detection of Cervical Intraepithelial Neoplasia. J. Clin. Microbiol. 58(3):e01443-01419. 2020. PMC7041584.

Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, Liu A, Siegel M, Bertha M, Panchia R, Li S, Cottle L, Rinehart A, Margolis D, Jennings A, McCauley M and Landovitz RJ. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. [Epub before print]. 2020. PMC7423859

Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Palumbo P, Buchanan AM, Vavro C, Singh R, Graham B, Anthony P, George K, Wiznia A and P1093 Study Team. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study. J. Pediatric Infect. Dis. Soc. 9(2):159-165. 2020. PMC4604048

Zia Y, Davis N, Wiener J, Hobbs MM, Lapple D, Chinula L, Tegha G, Msika A, Tang J and Kourtis AP. Factors associated with vaginal detection of prostate-specific antigen among participants in a clinical trial in Malawi. Sex. Transm. Infect. [Epub ahead of print]. 2020.

2019

Bekhbat M, Mehta CC, Kelly SD, Vester A, Ofotokun I, Felger J, Wingood G, Anastos K, Gustafson DR, Kassaye S, Milam J, Aouizerat B, Weber K, Golub ET, Moore MF, Diclemente R, Fischl M, Kempf M-C, Maki P, Neigh GN. HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling. Psychoneuroendocrinology. 2018 Oct;96:118–125. PMID: 29936334. PMCID: PMC6131054

Bertero L, Joseph SB, Trunfio M, Allice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. AIDS 2019 Mar 15;33(4):665–674. PMID:30608272

Chinula L, Nelson JAE, Wiener J, Tang JH, Hurst S, Tegha G, Msika A, Ellington S, Hosseinipour MC, Mataya R, Haddad LB, Kourtis AP. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial. Contraception. 2018 Sep;98(3):193–198. PMID: 29746813. PMCID: PMC6143482

Clutton G, Mollan K, Hudgens M, Goonetilleke N. A Reproducible, Objective Method Using MitoTracker® Fluorescent Dyes to Assess Mitochondrial Mass in T Cells by Flow Cytometry. Cytom Part J Int Soc Anal Cytol. 2018 Dec 21; PMID: 30576071. PMCID:PMC6461488

Colasanti J, Galaviz KI, Christina Mehta C, Palar K, Schneider MF, Tien P, Adimora AA, Alcaide M, Cohen MH, Gustafson D, Karim R, Merenstein D, Sharma A, Wingood G, Marconi VC, Ofotokun I, Ali MK. Room for Improvement: The HIV-Diabetes Care Continuum Over 15 Years in the Women’s Interagency HIV Study. Open Forum Infect Dis. 2018 Jun 1;5(6):ofy121. PMID: 29942823. PMCID: PMC6007350

Cranston RD, Cespedes MS, Paczuski P, Yang M, Coombs RW, Dragavon J, Saah A, Godfrey C, Webster-Cyriaque JY, Chiao EY, Bastow B, Wilkin T, ACTG 5298 Study Team. High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sex Transm Dis. 2018;45(4):266–271. PMID: 29528986. PMCID: PMC5868482

Dennis AM, Cohen MS, Rucinski KB, Rutstein SE, Powers KA, Pasquale DK, Phiri S, Hosseinipour MC, Kamanga G, Nsona D, Massa C, Hoffman IF, Pettifor AE, Miller WC. HIV-1 transmission among persons with acute HIV-1 infection in Malawi: demographic, behavioral and phylogenetic relationships. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 Nov 26; PMID: 30476007

Dumond JB, Greene SA, Prince HM, Chen J, Maas BM, Sykes C, Schauer AP, Blake KH, Nelson JAE, Gay CL, Kashuba ADM, Cohen MS. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. Antivir Ther. 2019;24(1):45–50. PMID: 30375984

Ewing AC, Ellington SR, Wiener JB, Chasela CS, Tegha G, Nelson JAE, Jamieson DJ, van der Horst C, Kourtis AP, BAN Study Team. Predictors of Perinatal HIV Transmission Among Women Without Prior Antiretroviral Therapy in a Resource-Limited Setting: The BAN Study. Pediatr Infect Dis J. 2018 Oct 30; PMID:30985546 . PMCID: PMC6302572

Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS. Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization. Cell Rep. 2018 Oct 30;25(5):1214–1224. PMID: 30380413. PMCID: PMC6226424

Gandhi M, Bacchetti P, Ofokotun I, Jin C, Ribaudo HJ, Haas DW, Sheth AN, Horng H, Phung N, Kuncze K, Okochi H, Landovitz RJ, Lennox J, Currier JS, AIDS Clinical Trials Group (ACTG) 5257 Study Team. Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019 Mar 5;68(6):1044–1047. PMID: 30184104. PMCID: PMC6399433

Garrido C, Tolstrup M, Søgaard OS, Rasmussen TA, Allard B, Soriano-Sarabia N, Archin NM, Margolis DM. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. AIDS 2019 Mar 15;33(4):605–613. PMID: 30830886. PMCID: PMC6400302

Gradissimo A, Lam J, Attonito JD, Palefsky J, Massad LS, Xie X, Eltoum I-E, Rahangdale L, Fischl MA, Anastos K, Minkoff H, Xue X, D’Souza G, Flowers LC, Colie C, Shrestha S, Hessol NA, Strickler HD, Burk RD. Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women. Cancer Epidemiol Prev Biomark. 2018 Dec 1;27(12):1407–1415. PMID: 30237251. PMCID: PMC6279505

Hightow-Weidman LB, Magnus M, Beauchamp G, Hurt CB, Shoptaw S, Emel L, Piwowar-Manning E, Mayer KH, Nelson LE, Wilton L, Watkins P, Whitfield D, Fields SD, Wheeler D. Incidence and Correlates of STIs among Black Men who have Sex with Men Participating in the HPTN 073 PrEP Study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019 Jan 7; PMID: 30615169

Kelly SG, Wu K, Tassiopoulos K, Erlandson KM, Koletar SL, Palella FJ, ACTG A5322 Study Team. Frailty is an independent risk factor for mortality, cardiovascular disease, bone disease and diabetes among aging adults with HIV. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018 Dec 24; PMID: 30590451

Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 Nov;15(11):e1002690. PMID: 30408115. PMCID: PMC6224042

Nag M, De Paris K, Fogle JE. Epigenetic modulation of CD8+ T cell function in lentivirus infections: a review. Viruses. 2018a;10(5):227. PMID: 29710792. PMCID: PMC5977220

Nag M, Wang Y, De Paris K, Fogle JE. Histone modulation blocks Treg-induced Foxp3 binding to the IL-2 promoter of virus-specific CD8+ T cells from feline immunodeficiency virus infected cats. Viruses. 2018b;10(6):E287. PMID: 29861472. PMCID: PMC6024775

Omana-Zapata I, Mutschmann C, Schmitz J, Gibson S, Judge K, Aruda Indig M, Lu B, Taufman D, Sanfilippo AM, Shallenberger W, Graminske S, McLean R, Hsen RI, d’Empaire N, Dean K, O’Gorman M. Accurate and reproducible enumeration of T-, B-, and NK lymphocytes using the BD FACSLyric 10-color system: A multisite clinical evaluation. PloS One. 2019;14(1):e0211207. PMID: 30689658. PMCID: PMC6349332

Prather AA, Epel ES, Portela Parra E, Coccia M, Puterman E, Aiello AE, Dhabhar FS. Associations between chronic caregiving stress and T cell markers implicated in immunosenescence. Brain Behav Immun. 2018 Oct;73:546–549. PMID: 29935942. PMCID: PMC6129414

Rutstein SE, Chen JS, Nelson JAE, Phiri S, Miller WC, Hosseinipour MC. High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up. AIDS Res Ther. 2019 Feb 22;16(1):5. PMID: 30795780. PMCID: PMC6385432

Scheidell JD, Beau De Rochars VM, Séraphin MN, Hobbs MM, Morris JG, Célestin JP, Cottler LB, Khan MR. Socioeconomic Vulnerability and Sexually Transmitted Infection Among Pregnant Haitian Women. Sex Transm Dis. 2018 Sep;45(9):626–631. PMID: 29697553. PMCID: PMC6086731

Shivakoti R, Ewald ER, Gupte N, Yang W-T, Kanyama C, Cardoso SW, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Pollard R, Detrick B, Balagopal A, Asmuth DM, Semba RD, Campbell TB, Golub J, Gupta A, NWCS 319 and ACTG PEARLS Study Team. Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clin Nutr Edinb Scotl. 2018 May 29; PMID: 29885777. PMCID: PMC6265110

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM. HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. Mol Ther J Am Soc Gene Ther. 2018 Oct 3;26(10):2496–2506. PMID: 30249388. PMCID: PMC6171327

Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. J Neurovirol. 2018 Feb;24(1):132–136. PMID: 29243133

Van Wagoner N, Fife K, Leone PA, Bernstein DI, Warren T, Panther L, Novak RM, Beigi R, Kriesel J, Tyring S, Koltun W, Lucksinger G, Morris A, Zhang B, McNeil LK, Tasker S, Hetherington S, Wald A. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. J Infect Dis. 2018 Nov 5;218(12):1890–1899. PMID:29982727

Wang Y, Nag M, Tuohy JL, De Paris K, Fogle JE. T Regulatory Cell Induced Foxp3 Binds the IL2, IFNγ, and TNFα Promoters in Virus-Specific CD8+ T Cells from Feline Immunodeficiency Virus Infected Cats. AIDS Res Hum Retroviruses. 2018;34(3):269–276. PMID: 29037051. PMCID: PMC5863085

Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD, Dellon ES, De Paris K, Nelson JAE, Gay CL, Kashuba ADM. Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women. Antivir Ther. 2018;23(6):495-504. PMID: 29714167

Wechsberg WM, Bonner CP, Zule WA, van der Horst C, Ndirangu J, Browne FA, Kline TL, Howard BN, Rodman NF. Addressing the nexus of risk: Biobehavioral outcomes from a cluster randomized trial of the Women’s Health CoOp Plus in Pretoria, South Africa. Drug Alcohol Depend. 2019 Feb 1;195:16–26. PMID: 30562676. PMCID: PMC6415667

Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, Hucks-Ortiz C, Kuo I, Lucas J, Magnus M, Mayer KH, Nelson LE, Hendrix CW, Piwowar-Manning E, Shoptaw S, Watkins P, Watson CC, Wilton L. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc. 2019 Feb;22(2):e25223. PMID: 30768776. PMCID: PMC6376611

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG, VHICS Study Team. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infect Dis. 2018 Jun;5(6):ofy103. PMID: 29977962. PMCID: PMC6016417

2018

Archin NM, Kirchherr JL, Sung JA, Clutton G, Sholtis K, Xu Y, Allard B, Stuelke E, Kashuba AD,
Kuruc JD, Eron J, Gay CL, Goonetilleke N, Margolis DM. Interval dosing with the HDAC
inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. 2017 Aug 1;127(8):3126–3135.
PMID: 28714868. PMCID: PMC5531421

Bellavia A, Williams PL, DiMeglio LA, Hazra R, Abzug MJ, Patel K, Jacobson DL, Van Dyke RB,
Geffner ME, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
P219/219C Study, and the Pediatric HIV/AIDS Cohort Study (PHACS). Delay in sexual
maturation in perinatally HIV-infected youths is mediated by poor growth. AIDS Lond Engl. 2017
Jun 1;31(9):1333–1341. PMID: 28358737. PMCID: PMC5472204

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B,
Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K,
Hakim J, Kumarasamy N, Campbell TB, ACTG PEARLS/A5175 Team. Herpes Simplex Virus
Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as
Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J
Infect Dis. 2017 15;215(6):907–910. PMID: 28453835. PMCID: PMC5406847

Chen J, Akhtari FS, Wagner MJ, Suzuki O, Wiltshire T, Motsinger-Reif AA, Dumond JB.
Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How
Does This Influence the Effect of Aging? Clin Transl Sci. 2018 Mar;11(2):226–236. PMID:
29205871. PMC5866997.

Cheng L, Yu H, Li G, Li F, Ma J, Li J, Chi L, Zhang L, Su L. Type I interferons suppress viral
replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI
Insight. 2017 Jun 15;2(12). PMID: 28614789. PMCID: PMC5470878

Cho H, Mbai I, Luseno WK, Hobbs M, Halpern C, Hallfors DD. School Support as Structural HIV
Prevention for Adolescent Orphans in Western Kenya. J Adolesc Health Off Publ Soc Adolesc
Med. 2018 Jan;62(1):44–51. PMID: 29107569. PMCID: PMC5742035

Dela Peña-Ponce MG, Rodriguez-Nieves J, Bernhardt J, Tuck R, Choudhary N, Mengual M,
Mollan KR, Hudgens MG, Peter-Wohl S, De Paris K. Increasing JAK/STAT Signaling Function
of Infant CD4(+) T Cells during the First Year of Life. Front Pediatr. 2017;5:15. PMID: 28271056.
PMCID: PMC5318443

Eke AC, Chakhtoura N, Kashuba A, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S,
Capparelli EV, Mirochnick M, IMPAACT P1026s Protocol Team. Rilpivirine Plasma and Cervico-
Vaginal Concentrations in Women During Pregnancy and Postpartum. J Acquir Immune Defic
Syndr. 2018 Mar 8; PMID: 29528944

Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-
Chibanda L, Coutsoudis A, Gnanashanmugam D, Chakhtoura N, McCarthy K, Mukuzunga C,
Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT,
Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE, PROMISE Study Team.
Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal
Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-
1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-
Label, Clinical Trial. J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383–392. PMID: 29239901.
PMC5825265.

Gallo MF, Legardy-Williams J, Steiner MJ, Macaluso M, Carter M, Hobbs MM, Hylton-Kong T,
Anderson C, Costenbader E, Warner L. Sexual Relationship Power and Semen Exposure
Among Female Patients at a Sexually Transmitted Infection Clinic in Kingston, Jamaica. Arch
Sex Behav. 2017 Oct;46(7):2157–2164. PMID: 27305908. PMCID: PMC5500443

Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron
JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK, A5321 Team.
Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV
Persistence or Inflammation Among Individuals on Suppressive ART. J Infect Dis. 2018 Feb 26;
PMID: 29529230

Gay CL, DeBenedette MA, Tcherepanova IY, Gamble A, Lewis WE, Cope AB, Kuruc JD,
McGee KS, Kearney MF, Coffin JM, Archin NM, Hicks CB, Eron JJ, Nicolette CA, Margolis
DM. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Res Hum Retroviruses. 2018 Jan;34(1):111–122. PMID: 28636433.
PMC5771540

Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM,
Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ, AIDS Clinical Trials
5326 Study Team. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected
Participants on Suppressive Antiretroviral Therapy. J Infect Dis. 2017 Jun 1;215(11):1725–1733.
PMID: 28431010. PMCID: PMC5790148

Ghulam-Smith M, Olson A, White LF, Chasela CS, Ellington SR, Kourtis AP, Jamieson DJ,
Tegha G, van der Horst CM, Sagar M. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody
Response Associates with Enhanced Transmission and Infant Morbidity. mBio. 2017 Oct
24;8(5). PMID: 29066544. PMCID: PMC5654929

Hampel D, Shahab-Ferdows S, Gertz E, Flax VL, Adair LS, Bentley ME, Jamieson DJ, Tegha
G, Chasela CS, Kamwendo D, van der Horst CM, Allen LH. The effects of a lipid-based nutrient
supplement and antiretroviral therapy in a randomized controlled trial on iron, copper, and zinc in
milk from HIV-infected Malawian mothers and associations with maternal and infant biomarkers.
Matern Child Nutr. 2018 Apr;14(2):e12503. PMID: 28851037. PMCID: PMC5832511

Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, Kaunda-
Khangamwa B, Compliment K, Stanley C, Cataldo F, van Lettow M, Rosenberg NE, Tweya H,
Gugsa S, Sampathkumar V, Schouten E, Eliya M, Chimbwandira F, Chiwaula L, Kapito-Tembo
A, Phiri S, PURE Malawi Consortium. Viral Suppression and HIV Drug Resistance at 6 Months
Among Women in Malawi’s Option B+ Program: Results From the PURE Malawi Study. J Acquir
Immune Defic Syndr 1999. 2017 Jun 1;75 Suppl 2:S149–S155. PMID: 28498184. PMCID:
PMC5431274

Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M,
McFarland EJ, Van Dyke RB, Jacobson D, Pediatric HIV/AIDS Cohort Study (PHACS)
Adolescent Master Protocol (AMP) study. Improvement in lipids after switch to boosted
atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease
inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018 Mar;19(3):175–183.
PMID: 29159965. PMCID: PMC5821593

Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez
AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ. Birth Weight and Preterm
Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected
Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT
P1025 Protocol. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Sep 15;65(6):982–989. PMID:
28575201. PMCID: PMC5849107

Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E,
Chakhtoura N, Burchett S, Mirochnick M, IMPAACT P1026s Protocol Team. Dolutegravir
pharmacokinetics in pregnant and postpartum women living with HIV. AIDS Lond Engl. 2018 Mar
27;32(6):729–737. PMID: 29369162. PMCID: PMC5854536

Patel S, Lam S, Sung J, Cruz R, Goonetilleke N, Xu Y, Kuruc J, Gay C, Jones B, Shpall E,
Margolis D, Ambinder R, Bollard C. HIV specific T cells generated from HIV naive adult
and cord blood donors target a range of novel viral epitopes – implications for a cure
strategy after allogeneic HSCT and CBT. Cytotherapy. 2017;19:S41-2. (poster abstract)

Pinto JA, Capparelli EV, Warshaw M, Zimmer B, Cressey TR, Spector SA, Qin M, Smith B,
Siberry GK, Mirochnick M, IMPAACT P1083 Team. A Phase II/III Trial of Lopinavir/Ritonavir
Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pediatr Infect Dis J.
2018 Feb;37(2):e29–e35. PMID: 29088027. PMCID: PMC5762400

Scheidell J, Beau De Rochars V, Séraphin M, Hobbs M, Morris J, Célestin J, Cottier L, Khan M.
Socioeconomic Vulnerability and Sexually Transmitted Infection among Pregnant Haitian
Women. Sex Transm Dis. 2018;Sep;45(9):626-631. PMID: 29697553 PMCID: PMC6086731.

Seña AC, Lee JY, Schwebke J, Philip SS, Wiesenfeld HC, Rompalo AM, Cook RL, Hobbs MM.
A silent epidemic: the prevalence, incidence and persistence of Mycoplasma genitalium among
young, asymptomatic high-risk women in the United States. Clin Infect Dis Off Publ Infect Dis
Soc Am. 2018 Jan 12; PMID: 29342269

Smith JS, Des Marais AC, Deal AM, Richman AR, Perez-Heydrich C, Yen-Lieberman B, Barclay
L, Belinson J, Rinas A, Brewer NT. Mailed Human Papillomavirus Self-Collection With
Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm
Dis. 2018 Jan;45(1):42–48. PMID: 28876298. PMCID: PMC5846187

Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM,
Margolis DM. Vorinostat Renders the Replication-Competent Latent Reservoir of Human
Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine. 2017
Sep;23:52–58. PMID: 28803740. PMCID: PMC5605299

Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E,
Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A pilot study of dolutegravir
plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000
copies/mL. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017 Dec 14; PMID: 29253097. PMCID: PMC5961075.

Utay NS, Kitch DW, Yeh E, Fichtenbaum CJ, Lederman MM, Estes JD, Deleage C, Magyar C,
Nelson SD, Klingman KL, Bastow B, Luque AE, McComsey GA, Douek DC, Currier JS, Lake JE,
A5317 team. Telmisartan Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than
Continued ART Alone. J Infect Dis. 2018 Feb 1; PMID: 29401318. PMC5946950.

Warshaw MG, Siberry GK, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J.
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in
Previously Immunized HIV-Infected Children and Youth. J Pediatr Infect Dis Soc. 2017 Sep
1;6(3):e69–e74. PMID: 28339668. PMCID: PMC5907864.

Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, Shaheen NJ, Madanick RD,
Dellon ES, De Paris K, Nelson JAE, Gay CL, Kashuba ADM. Virologic and Immunologic
Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIVInfected
Men and Women. Antivir Ther. 2018;in press.

2017

Celum C, Hong T, Cent A, Donnell D, Morrow R, Baeten JM, Firnhaber C, Grinsztejn B,
Hosseinipour MC, Lalloo U, Nyirenda M, Riviere C, Sanchez J, Santos B, Supparatpinyo K,
Hakim J, Kumarasamy N, Campbell TB, ACTG PEARLS/A5175 Team. Herpes Simplex Virus
Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J
Infect Dis. 2017 15;215(6):907–910. PMID: 28453835. PMCID: PMC5406847